MAPK14 Polyclonal Antibody

Sizes: 60μL, 120μL, 200μL

Catalogue Numbers: E-AB-52163-60, E-AB-52163-120, E-AB-52163-200

Citations, Manuals and MSDS Available upon request.

Abbreviation: MAPK14

Target Synonym: CSAID Binding Protein 1; CSAID binding protein; CSAID-binding protein; Csaids binding protein; CSBP 1; CSBP 2; CSBP; CSBP1; CSBP2; CSPB1; Cytokine suppressive anti-inflammatory drug-binding protein; EXIP; MAP kinase 14; MAP kinase MXI2; MAP kinase p38 alpha; MAPK 14; MAPK14; MAX interacting protein 2; MAX-interacting protein 2; Mitogen Activated Protein Kinase 14; Mitogen activated protein kinase p38 alpha; Mitogen-activated protein kinase 14; Mitogen-activated protein kinase p38 alpha; MK14; Mxi 2; MXI2; p38 ALPHA; p38; p38 MAP kinase; p38 MAPK; p38 mitogen activated protein kinase; p38ALPHA; p38alpha Exip; PRKM14; PRKM15; RK; SAPK2A

Research Areas: Cancer, Immunology, Signal Transduction

Conjugation: Unconjugated

Host: Rabbit

Species Reactivity: Human, Mouse, Rat

Application: IHC, ELISA

Isotype: IgG

Clonality: Polyclonal

UNIProt ID: Q16539

Background: MAPK14(mitogen-activated protein kinase 14) is also named as SAPK2A, p38MAPK, CSBP1, RK, p38, EXIP, Mxi2, CSBP2, PRKM14, PRKM15, CSPB1, p38ALPHA and belongs to the MAP kinase subfamily. MAPK14-signaling is a central pathway for the integration of instructive signals in dendritic cells for T(H)17 differentiation and inflammation. It plays an important role in the regulation of hematopoietic stem cellself-renewal in vitro and inhibition of MAPK14 activation with a small molecule inhibitor may represent a novel approach to promote ex vivo expansion of hematopoietic stem cell. This protein has 4 isoforms produced by alternative splicing.

Concentration: 1.2 mg/mL

Immunogen: Fusion protein of human MAPK14

Buffer: PBS with 0.05% NaN3 and 40% Glycerol, pH7.4

Purification Method: Antigen affinity purification

Dilution: IHC 1:50-1:200, ELISA 1:5000-1:10000

Storage: -20°C/One year. Avoid freeze / thaw cycles.

Shipping: Ice bag

Research Use Only